Weight Management

Eloralintide

LY3841136 · Lilly eloralintide

Eli Lilly investigational long-acting amylin receptor agonist (eloralintide / LY3841136). Not amycretin. Not petrelintide. Not a compounded amylin cake.

Not FDA-approved - research chemical

Quick answer

What it is: Eli Lilly investigational long-acting amylin receptor agonist (eloralintide / LY3841136).

Typical research dose: Investigational - sponsor protocol only

Open the calculator →GLP-1 cost: Medicare, brand-name direct and compounded →GLP-1 with insurance or Medicare ($25 / $50 routes) →Online GLP-1 providers compared →

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: September 2026·Evidence: Emerging

Typical research dose

Investigational - sponsor protocol only

Frequency

Trial schedules only

Half-life

Long-acting program (sponsor PK)

Common vials

N/A (oral)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Metabolic / weight5.5/10
Lilly amylin program. Haircut: investigational; not amycretin; not a cake.

Compound card

Sequence: Long-acting amylin agonist (LY3841136 / eloralintide)
Class: Investigational long-acting amylin receptor agonist (Eli Lilly)
Formula: Amylin analog (proprietary)
Status: Not FDA-approved · research use

How it works

Eloralintide (LY3841136) is Eli Lilly’s investigational long-acting amylin receptor agonist. Mechanism class matches the amylin satiety story; it is not amycretin (dual amylin/GLP-1), not petrelintide, and not pramlintide.

Source: Eli Lilly clinical program disclosures; not a finished US label

Research Use Cases

✓Amylin pipeline literacy: Moderate
✓DIY reconstitution: Low

Dosing

Phase	Dose	Frequency	Notes
Human care	Sponsor protocol only	Trial schedule	Not a DIY titration.
Research-chem SKU	Do not invent	n/a	No honest cake chart.

Administration

Route / form

Parenteral under clinical protocol

Timing

Program-defined

Empty stomach?

No - Food timing is not critical.

Timeline

Trial programs

Sponsor-owned endpoints only.

Who it is for

Amylin pipeline literacy

Moderate

Name disambiguation vs amycretin matters.

DIY reconstitution

Low

Wrong tool.

Safety & Considerations

Investigational amylin-class GI risk. Unverified vials are identity risk. Clinical stacking with insulin is a clinician problem, not a forum protocol.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

Not amycretin (dual amylin/GLP-1).
Not petrelintide or cagrilintide.
Sponsor protocols ≠ research-chem doses.
This site will not treat obesity from this leaf.

Verdict

Eloralintide is Lilly’s long-acting amylin agonist. Not amycretin. Not petrelintide. Not a compounded amylin cake.

Interactions & Contraindications

Investigational amylin-class GI risk. Unverified vials are identity risk. Clinical stacking with insulin is a clinician problem, not a forum protocol.

Frequently Asked Questions

Is eloralintide amycretin?▼

No. Amycretin is dual amylin/GLP-1. Eloralintide is an amylin-pathway agonist program.

Is there a reconstitution example?▼

Not an honest one for gray-market fill. Skip the calculator.

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide

14 min read • Pillar Guide

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library